医学
肺癌
耐受性
靶向治疗
埃罗替尼
肿瘤科
表皮生长因子受体
内科学
生物信息学
癌症
不利影响
生物
作者
Julian A. Marin‐Acevedo,Bruna Pellini,ErinMarie O. Kimbrough,J. Kevin Hicks,Alberto Chiappori
出处
期刊:Cancers
[Multidisciplinary Digital Publishing Institute]
日期:2023-01-19
卷期号:15 (3): 629-629
被引量:20
标识
DOI:10.3390/cancers15030629
摘要
The development of targeted therapies over the past two decades has led to a dramatic change in the management of EGFR-mutant non-small cell lung cancer (NSCLC). While there are currently five approved EGFR tyrosine kinase inhibitors (TKIs) for treating EGFR-mutant NSCLC in the first-line setting, therapy selection after progression on EGFR TKIs remains complex. Multiple groups are investigating novel therapies and drug combinations to determine the optimal therapy and treatment sequence for these patients. In this review, we summarize the landmark trials and history of the approval of EGFR TKIs, their efficacy and tolerability, and the role of these therapies in patients with central nervous system metastasis. We also briefly discuss the mechanisms of resistance to EGFR TKIs, ongoing attempts to overcome resistance and improve outcomes, and finalize by offering treatment sequencing recommendations.
科研通智能强力驱动
Strongly Powered by AbleSci AI